|
1
|
Raghavendra V, Rutkowski MD and DeLeo JA:
The role of spinal neuroimmune activation in morphine
tolerance/hyperalgesia in neuropathic and sham-operated rats. J
Neurosci. 22:9980–9989. 2002.PubMed/NCBI
|
|
2
|
Horvath RJ, Romero-Sandoval EA and De Leo
JA: Inhibition of microglial P2X4 receptors attenuates morphine
tolerance, Iba1, GFAP and mu opioid receptor protein expression
while enhancing perivascular microglial ED2. Pain. 150:401–413.
2010. View Article : Google Scholar
|
|
3
|
Ramos KM, Lewis MT, Morgan KN, et al:
Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone:
therapeutic efficacy in a range of experimental nervous system
disorders. Neuroscience. 169:1888–1900. 2010. View Article : Google Scholar
|
|
4
|
Johnston IN, Milligan ED, Wieseler-Frank
J, et al: A role for proinflammatory cytokines and fractalkine in
analgesia, tolerance, and subsequent pain facilitation induced by
chronic intrathecal morphine. J Neurosci. 24:7353–7365. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hutchinson MR, Bland ST, Johnson KW, Rice
KC, Maier SF and Watkins LR: Opioid-induced glial activation:
mechanisms of activation and implications for opioid analgesia,
dependence, and reward. ScientificWorldJournal. 7:98–111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woodruff TM, Ager RR, Tenner AJ, Noakes PG
and Taylor SM: The role of the complement system and the activation
fragment C5a in the central nervous system. Neuromolecular Med.
12:179–192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kemper C and Atkinson JP: T-cell
regulation: with complements from innate immunity. Nat Rev Immunol.
7:9–18. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ehrnthaller C, Ignatius A, Gebhard F and
Huber-Lang M: New insights of an old defense system: structure,
function, and clinical relevance of the complement system. Mol Med.
17:317–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ricklin D, Hajishengallis G, Yang K and
Lambris JD: Complement: a key system for immune surveillance and
homeostasis. Nat Immunol. 11:785–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huber-Lang MS, Riedeman NC, Sarma JV, et
al: Protection of innate immunity by C5aR antagonist in septic
mice. FASEB J. 16:1567–1574. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Recknagel S, Bindl R, Kurz J, et al:
C5aR-antagonist significantly reduces the deleterious effect of a
blunt chest trauma on fracture healing. J Orthop Res. 30:581–586.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hecke F, Schmidt U, Kola A, Bautsch W,
Klos A and Kohl J: Circulating complement proteins in multiple
trauma patients – correlation with injury severity, development of
sepsis, and outcome. Crit Care Med. 25:2015–2024. 1997.
|
|
13
|
Ganter MT, Brohi K, Cohen MJ, et al: Role
of the alternative pathway in the early complement activation
following major trauma. Shock. 28:29–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gerard C: Complement C5a in the sepsis
syndrome – too much of a good thing? N Engl J Med. 348:167–169.
2003.
|
|
15
|
Liang DY, Li X, Shi X, et al: The
complement component C5a receptor mediates pain and inflammation in
a postsurgical pain model. Pain. 153:366–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jacob A, Hack B, Bai T, Brorson JR, Quigg
RJ and Alexander JJ: Inhibition of C5a receptor alleviates
experimental CNS lupus. J Neuroimmunol. 221:46–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jang JH, Liang D, Kido K, Sun Y, Clark DJ
and Brennan TJ: Increased local concentration of complement C5a
contributes to incisional pain in mice. J Neuroinflammation.
8:802011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fonseca MI, Ager RR, Chu SH, et al:
Treatment with a C5aR antagonist decreases pathology and enhances
behavioral perfor mance in murine models of Alzheimer’s disease. J
Immunol. 183:1375–1383. 2009.PubMed/NCBI
|
|
19
|
Yaksh TL and Rudy TA: Analgesia mediated
by a direct spinal action of narcotics. Science. 192:1357–1358.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stein C, Gramsch C and Herz A: Intrinsic
mechanisms of antinociception in inflammation: local opioid
receptors and beta-endorphin. J Neurosci. 10:1292–1298.
1990.PubMed/NCBI
|
|
21
|
Raghavendra V, Tanga FY and DeLeo JA:
Attenuation of morphine tolerance, withdrawal-induced hyperalgesia,
and associated spinal inflammatory immune responses by
propentofylline in rats. Neuropsychopharmacology. 29:327–334. 2004.
View Article : Google Scholar
|
|
22
|
Kamei J, Ohsawa M, Hayashi SS and
Nakanishi Y: Effect of chronic pain on morphine-induced respiratory
depression in mice. Neuroscience. 174:224–233. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song P and Zhao ZQ: The involvement of
glial cells in the development of morphine tolerance. Neurosci Res.
39:281–286. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hutchinson MR, Lewis SS, Coats BD, et al:
Possible involvement of toll-like receptor 4/myeloid
differentiation factor-2 activity of opioid inactive isomers causes
spinal proinflammation and related behavioral consequences.
Neuroscience. 167:880–893. 2010. View Article : Google Scholar
|
|
25
|
Rus H and Niculescu F: The complement
system in central nervous system diseases. Immunol Res. 24:79–86.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rus H, Cudrici C, David S and Niculescu F:
The complement system in central nervous system diseases.
Autoimmunity. 39:395–402. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu L, Aldskogius H and Svensson M:
Ultrastructural localization of immunoglobulin G and complement C9
in the brain stem and spinal cord following peripheral nerve
injury: an immunoelectron microscopic study. J Neurocytol.
27:737–748. 1998. View Article : Google Scholar
|
|
28
|
Davoust N, Jones J, Stahel PF, Ames RS and
Barnum SR: Receptor for the C3a anaphylatoxin is expressed by
neurons and glial cells. Glia. 26:201–211. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Twining CM, Sloane EM, Schoeniger DK, et
al: Activation of the spinal cord complement cascade might
contribute to mechanical allodynia induced by three animal models
of spinal sensitization. J Pain. 6:174–183. 2005. View Article : Google Scholar
|
|
30
|
Rioux P: TP-10 (AVANT Immunotherapeutics).
Curr Opin Investig Drugs. 2:364–371. 2001.
|
|
31
|
Shen Y and Meri S: Yin and Yang:
complement activation and regulation in Alzheimer’s disease. Prog
Neurobiol. 70:463–472. 2003.PubMed/NCBI
|
|
32
|
Sun T, Song WG, Fu ZJ, Liu ZH, Liu YM and
Yao SL: Alleviation of neuropathic pain by intrathecal injection of
antisense oligo-nucleotides to p65 subunit of NF-kappaB. Br J
Anaesth. 97:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Z, Ma W, Chabot JG and Quirion R:
Calcitonin gene-related peptide as a regulator of neuronal
CaMKII-CREB, microglial p38–NFkappaB and astroglial ERK-Stat1/3
cascades mediating the development of tolerance to morphine-induced
analgesia. Pain. 151:194–205. 2010.PubMed/NCBI
|
|
34
|
Ischenko A, Sayah S, Patte C, et al:
Expression of a functional anaphylatoxin C3a receptor by
astrocytes. J Neurochem. 71:2487–2496. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
O’Barr S and Cooper NR: The C5a complement
activation peptide increases IL-1beta and IL-6 release from
amyloid-beta primed human monocytes: implications for Alzheimer’s
disease. J Neuroimmunol. 109:87–94. 2000.PubMed/NCBI
|
|
36
|
Osaka H, McGinty A, Hoepken UE, Lu B,
Gerard C and Pasinetti GM: Expression of C5a receptor in mouse
brain: role in signal transduction and neurodegeneration.
Neuroscience. 88:1073–1082. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
O’Barr SA, Caguioa J, Gruol D, et al:
Neuronal expression of a functional receptor for the C5a complement
activation fragment. J Immunol. 166:4154–4162. 2001.PubMed/NCBI
|
